Bortezomib vs Romidepsin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Bortezomib or Romidepsin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Bortezomib and Romidepsin?
Bortezomib inhibits the 26S proteasome; romidepsin inhibits histone deacetylases (HDAC) - fundamentally different epigenetic/proteostatic mechanisms used in different hematologic cancers.
Evidence Comparison
Bortezomib: FDA approved for multiple myeloma and mantle cell lymphoma, with extensive Phase 3 data making it a standard-of-care backbone. Romidepsin: FDA approved 2009 for cutaneous T-cell lymphoma (CTCL) and 2011 for peripheral T-cell lymphoma (PTCL), with smaller Phase 2 registrational studies. Bortezomib has broader and larger clinical trial data.
Evidence Context Favoring Bortezomib
Multiple myeloma or mantle cell lymphoma treatment or research - bortezomib is a backbone agent.
Evidence Context Favoring Romidepsin
T-cell lymphoma (CTCL/PTCL) treatment or HDAC inhibition research - romidepsin is the approved agent for these specific indications.
Side-by-Side Snapshot
| Evidence grade | Bortezomib: Level A Romidepsin: Level A |
|---|---|
| Research status | Bortezomib: FDA Approved Romidepsin: FDA Approved |
| Primary category | Bortezomib: Immune Support Romidepsin: Immune Support |
| Cited studies | Bortezomib: 3 Romidepsin: 3 |